Clinical and imaging tools in the early diagnosis of prostate cancer, a review

JBR-BTR

Volumn 93, Issue 2, 2010, Pages 62-70

  De Visschere, P ^a   Oosterlinck, W ^a   De Meerleer, G ^a   Villeirs, G ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; GADOLINIUM CHELATE; PROSTATE SPECIFIC ANTIGEN; SCOPOLAMINE;

CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CLINICAL ASSESSMENT TOOL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DIGITAL RECTAL EXAMINATION; DISTANT METASTASIS; DOPPLER FLOWMETRY; EARLY DIAGNOSIS; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY;

EID: 77952852853     PISSN: 17802393     EISSN: None     Source Type: Journal    
DOI: 10.5334/jbr-btr.121     Document Type: Conference Paper

References (41)

1. Fuchsjager M., Shukla-Dave A., Akin O., Barentsz J., Hricak H.: Prostate cancer imaging. Acta Radiol, 2008, 49: 107-120.
2. Mazaheri Y., Shukla-Dave A., Muellner A., Hricak H.: MR imaging of the prostate in clinical practice. Magma, 2008, 21: 379-392.
3. Catalona W.J., Loeb S.:The PSA era is not over for prostate cancer. Eur Urol, 2005, 48: 541-545. (Pubitemid 41278577)
4. Candefjord S., Ramser K., Lindahl O.A.: Technologies for localization and diagnosis of prostate cancer. J Med Eng Technol, 2009, 33: 585-603.
5. Verbaeys C., Oosterlinck W.: Prostaatspecifiek antigeen (PSA): indicatie, interpretatie en therapeutisch gevolg. Tijdschrift voor Geneeskunde, 2008, 64: 609-613. (Pubitemid 351947206)
6. Schroder F.H., Roobol M.J.: Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol, 2009, 19: 227-231.
7. Catalona W.J., Southwick P.C., Slawin K.M., et al.: Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology, 2000, 56: 255-260.
8. Shteynshlyuger A., Andriole G.L.: Prostate cancer: to screen or not to screen? Urol Clin North Am, 37: 1-9, Table of Contents.
9. Schroder F.H., Hugosson J., Roobol M.J., et al.: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med, 2009, 360: 1320-1328.
10. Pallwein L., Mitterberger M., Pelzer A., et al.: Ultrasound of prostate cancer: recent advances. Eur Radiol, 2008,18: 707-715. (Pubitemid 351447775)
11. Lin D.W.: Beyond P.S.A.: utility of novel tumor markers in the setting of elevated PSA. Urol Oncol, 2009, 27: 315-321.
12. Schilling D., de Reijke T., Tombal B., de la Taille A., Hennenlotter J., Stenzl A.: The Prostate Cancer Gene 3 assay: indications for use in clinical practice. BJU Int, 2009, 105: 452-455.
13. Kirby R.S., Fitzpatrick J.M., Irani J.: Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU lnt, 2009, 103: 441-445.
14. Kijvikai K.: Digital rectal examination, serum prostatic specific antigen or transrectal ultrasonography: the best tool to guide the treatment of men with benign prostatic hyperplasia. Curr Opin Urol, 2009, 19: 44-48.
15. Bosch J.L., Bohnen A.M., Groeneveld F.R: Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. Eur Urol, 2004, 46: 753-759.
16. Lawrentschuk N., Fleshner N.: The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU lnt, 2009, 103: 730-733.
17. McMahon C.J., Bloch B.N., Lenkinski R.E., Rofsky N.M.: Dynamic contrast-enhanced MR imaging in the evaluation of patients with prostate cancer. Magn Reson Imaging Clin N Am, 2009, 17: 363-383.
18. Afnan J., Tempany C.M.: Update on prostate imaging. Urol Clin North Am, 37:23-25, Table of Contents.
19. Gravas S., Mamoulakis C., Rioja J., et al.: Advances in ultrasound technology in oncologic urology. Urol Clin North Am, 2009, 36: 133-145, vii.
20. Pallwein L., Mitterberger M., Struve P., et al.: Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur Radiol, 2007, 17: 2278-2285. (Pubitemid 47288264)
21. Feleppa E.J., Porter C.R., Ketterling J., et al.: Recent developments in tissue-type imaging (TTI) for planning and monitoring treatment of prostate cancer. Ultrason Imaging, 2004, 26: 163-172. (Pubitemid 40571126)
22. Kim C.K., Park B.K.: Update of prostate magnetic resonance imaging at 3 T. J Comput Assist Tomogr, 2008, 32: 163-172. (Pubitemid 351489432)
23. Somford D.M., Futterer J.J., Hambrock T., Barentsz J.O.: Diffusion and perfusion MR imaging of the prostate. Magn Reson Imaging Clin N Am, 2008,16: 685-695, ix.
24. Seitz M., Shukla-Dave A., Bjartell A., et al.: Functional magnetic resonance imaging in prostate cancer. Eur Urol, 2009, 55: 801-814.
25. Van As N., Charles-Edwards E., Jackson A., et al.: Correlation of diffusion-weighted MRI with whole mount radical prostatectomy specimens. Br J Radiol, 2008, 81: 456-462. (Pubitemid 351957756)
26. Li H., Sugimura K., Kaji Y., et al.: Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. AJR Am J Roentgenol, 2006, 186: 729-742. (Pubitemid 46100257)
27. Ocak I., Bernardo M., Metzger G., et al.: Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol, 2007, 189: 849.
28. Futterer J.J., Heijmink S.W., Scheenen T.W., et al.: Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology, 2006, 241: 449-458. (Pubitemid 44632891)
29. Kurhanewicz J., Vigneron D.B.: Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am, 2008, 16: 697-710, ix-x.
30. Shukla-Dave A., Hricak H., Moskowitz C., et al.: Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology, 2007, 245: 499-506. (Pubitemid 47612532)
31. Kurhanewicz J., Vigneron D., Hricak H., Narayan R., Carroll R., SJ. N. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology, 1996,, 198: 795-805. (Pubitemid 26066301)
32. Zakian K.L., Sircar K., Hricak H., et al.: Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analasis after radical prostatectomy. Radiology, 2005, 234: 804-814. (Pubitemid 40250824)
33. Villeirs G.M., De Meerleer G.O., De Visschere P.J., Fonteyne V.H., Verbaeys A.C., Oosterlinck W.: Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: A single-institution experience of 356 patients. Eur J Radiol, 2009.
34. Sato C., Naganawa S., Nakamura T., et al.: Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging, 2005,21:258-262. (Pubitemid 40280120)
35. Yoshimitsu K., Kiyoshima K., Irie H., et al.: Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging, 2008, 27: 132-139.
36. Chen M., Dang HD., Wang JY, et al.: Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined. Acta Radiol, 2008, 49: 602-610.
37. desouza N.M., Reinsberg S.A., Scurr E.D., Brewster J.M., Payne G.S.: Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules. Br J Radiol, 2007, 80: 90-95.
38. Haider M.A., Chung R., Sweet J., et al.: Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. lnt J Radiat Oncol Biol Phys, 2008, 70: 425-430.
39. Emonds K.M., Swinnen J.V., Mortelmans L., Mottaghy F.M.: Molecular imaging of prostate cancer. Methods, 2009, 48:, 193-199.
40. Grenier N., Quesson B., de Senneville B.D., Trillaud H., Couillaud F., Moonen C.: Molecular MR imaging and MR-guided ultrasound therapies in cancer. Jbr-Btr, 2009, 92: 8-12.
41. Bouchelouche K., Oehr R: Recent developments in urologic oncology: positron emission tomography molecular imaging. Curr Opin Oncol, 2008, 20: 321-326. (Pubitemid 351507554)